La régulation et le contrôle-qualité de l'expression génique permettent respectivement de maintenir un équilibre entre synthèse et dégradation des ARNm répondant aux besoins cellulaires et d'empêcher l'expression d'ARNm ou protéines aberrants potentiellement toxiques. Pour mieux comprendre ces processus cytoplasmiques, je me suis intéressée à Jlp2, Tac4 et Ska1, trois protéines ayant des liens physiques ou fonctionnels avec des acteurs du contrôle-qualité des ARNm et peptides appartenant aux complexes RQC et SKI. Jlp2 montre des liens de létalité synthétique avec les complexes RQC et SKI mais son absence n'altère pas le " NonStop mRNA Decay ". Elle pourrait donc être impliquée dans une autre voie de contrôle dépendante des complexes RQC et SKI. Tac4 est une ARN hélicase putative associée aux ribosomes, au niveau de l'hélice H16 de l'ARNr 18S comme son homologue putatif mammifère DHX29. Elle interagit également au niveau de régions 3'UTR d'ARNm. Ces observations suggèrent que Tac4 pourrait être impliquée dans la réinitiation de la traduction et le sauvetage de ribosomes non-dissociés récemment identifiés dans la région 3'UTR d'ARNm. Enfin, nous avons identifié Ska1, une protéine appartenant à une nouvelle sous-population de complexes SKI. Nos données suggèrent que ce complexe SKI-Ska1 est impliqué dans la dégradation de transcrits dépourvus de ribosome. Nous proposons un modèle selon lequel ce complexe SKI-Ska1 agirait durant la dégradation de 3'UTR avec l'exosome, puis en arrivant dans la région codante et en rencontrant un ribosome, Ska1 se dissocierait du complexe pour lui permettre d'interagir directement avec le ribosome et poursuivre la dégradation 3'-5' de l'ARN. / Mechanisms responsible for the regulation of gene expression and its quality-control are required, respectively for maintaining an equilibrium between mRNA synthesis and degradation and to prevent synthesis of aberrant mRNAs and proteins potentially toxic for the cells. To better understand these quality-control processes, I studied three factors, Jlp2, Tac4 and Ska1, with physical or functional links described with factors involved in mRNA and protein quality-control, the RQC and SKI complexes. Jlp2 shows synthetic lethality with the RQC and SKI complexes but its deletion has no effect on the NonStop mRNA Decay, suggesting that Jlp2 could be implicated in another control pathway linked to the RQC and SKI complexes. Tac4 is a putative RNA helicase bound to ribosomes, on the 18S rRNA H16 helix, as its mammalian putative homolog DHX29. DHX29 plays a role in translation initiation but surprisingly, Tac4 interacts, in addition to ribosomes, with mRNA 3’UTRs. These observations suggest that Tac4 could be implicated in translation reinitiation and rescue of non-dissociated-ribosomes, recently described within mRNA 3’UTRs. Finally, we identified Ska1, a new factor associated to a SKI complex subpopulation. Our observations suggest that the SKI-Ska1 complex is implicated in the degradation of transcripts devoid of ribosomes. It suggests a model by which the SKI complex would proceed in two steps. First, the SKI-Ska1 complex could assist the exosome to degrade 3’UTR regions of RNAs and then, when its reaches the coding region and encounter a ribosome, Ska1 would leave the complex and allow it to interact directly with ribosomes to proceed further in the 3’-5’ RNA degradation.

Exosomen aus Zellen nehmen eine immer größere Rolle in aktuellen Erkenntnissen zu Tumorwachstum und Metastasierung ein. Die Funktionen dieser circa 40-100 nm großen, aktiv sezernierten Vesikel sind bisher noch weitesgehend ungeklärt. Für die Untersuchung von Exosomen sind optimierte und schonende Isolierungsmethoden notwendig. Zur Zeit gibt es jedoch weder eine standardisierte Methode zur routinemäßigen Isolation von Exosomen noch zur Isolation von funktionell intakten Exosomen für die anschließende Funktionsanalyse. Ziel dieser Arbeit war es, eine vereinfachte, größenbasierte und standardisierbare Methode zur Isolation von funktionell intakten Exosomen zu entwickeln und die isolierten Exosomen qualitativ und quantitativ zu charakterisieren. Die Ergebnisse dieser Arbeit konnten in einer internationalen Fachzeitschrift publiziert werden. Die Publikation liegt dieser Arbeit bei (Heinemann et al. 2014).

Trichomonas vaginalis is a causative agent of the most common non-viral sexually transmitted disease with approximately 275 mil new cases annually. Virulence of this parasitic depends on at least four factors: cell shape transformation, cytoadherence, secretion of cysteine proteases, and presence of endosymbionts. Over the past decades, extracellular vesicles appeared being another important player in the host-parasite interaction. It was discovered that T. vaginalis is one of the protists that can shed the extracellular vesicles such as exosomes and ectosomes. These vesicles are possibly involved in host-parasite communications, however limited information is available about their function. To investigate a possible role of exosomes in T. vaginalis virulence, we first selected suitable strain, which is free of endosymbionts (TV 17-2MI). Next we prepared six clones of TV 17-2MI strain to test whether the strain is homogenous concerning the virulence, or there are differences in virulence among individual cells. Mouse intraperitoneal virulence tests revealed that the clones displayed significant differences in virulence level, particularly in abscess formation and mortality of infected animals. Thus, for the first time we demonstrated heterogeneity of cells derived from a single T. vaginalis strain...

The life-cycle of RNA is determined by several processing steps, which allow the cell to export and translate a coding transcript. The cell has developed an astonishingly complex mechanism to ensure the integrity of RNA processing steps. The quality control mechanism of RNA balances the biosynthesis and degradation of various transcripts, adding another layer of gene regulation to the complex system of gene expression. The exosome is a central piece of the RNA quality control mechanism as it degrades many of the aberrant or non-functional RNAs in the nucleus and the cytoplasm. This project characterizes and highlight a response to mutation of components from the RNA quality control mechanism in Saccharomyces cerevisiae. These perturbations include functional components of the exosome (Csl4 and Dis3), a cofactor of the nuclear exosome (Rrp6), an essential protein for pre-rRNA processing (Enp1) and a component of RNA export machinery (Srm1). Here, I present bioinformatics approaches to characterize the cellular response at a level of transcript expression and polyadenylation size. The stress response embedded in the gene expression profile is highly similar between the mutants. This work suggests a generic response to a failure in different components of the RNA quality control machinery. / Le cycle de vie des ARN est déterminé par différentes étapes permettant à la cellule d’exporter et de traduire un transcrit codant. La cellule a développé un mécanisme incroyablement complexe pour s’assurer de l’intégrité des étapes de maturation de l’ARN. Le mécanisme de contrôle de qualité balance la biosynthèse et la dégradation de différents transcrits, ce qui ajout un niveau de régulation au système de l’expression génique. L’exosome est une pièce centrale du mécanisme de contrôle de qualité de l’ARN alors qu’elle dégrade une grande partie des transcrits aberrants ou non-fonctionnels dans le noyau et le cytoplasme. Ce projet caractérise et souligne la réponse cellulaire à la suite de la mutation de composantes du mécanisme de contrôle de qualité de l’ARN chez Saccharomyces cerevisiae. Ces perturbations comportent des composantes fonctionnelles du complexe de l’exosome (Csl4 et Dis3), un cofacteur de l’exosome nucléaire (Rrp6), une protéine essentielle pour la maturation des pré-ARNr (Enp1) et une composante de la machinerie d’export de l’ARN (Srm1). Ici, je présente des approches bio-informatiques pour caractériser la réponse cellulaire au niveau de l’expression des transcrits et de la taille des segments polyadénylés. La réponse au stress cellulaire intégré dans le profil d’expression du génome est très similaire entre les mutants. Ce travail suggère une réponse générique à la suite de la perturbation de différentes composantes du mécanisme de contrôle de qualité de l’ARN.

No description available.

O exossomo é um complexo multiproteico conservado evolutivamente de archaea a eucariotos superiores que desempenha funções celulares essenciais tais como: atividade exoribonucleolítica 3\'→5\', regulação dos níveis de mRNA, maturação de RNAs estruturais e controle de qualidade de RNAs durante os vários estágios do mecanismo de expressão gênica. Em Archaea, o exossomo é composto por até quatro subunidades diferentes, duas com domínios de RNase PH, aRrp41 e aRrp42, e duas com domínios de ligação a RNAs, aCsl4 e aRrp4. Três cópias das proteínas aRrp4 e/ou aCsl4 se associam com o núcleo hexamérico catalítico do anel de RNase PH e completam a formação do complexo. A proteína PaNip7 é um cofator de regulação do exossomo da archaea Pyrococcus abyssi e atua na inibição do complexo enzimático ligando-se simultaneamente ao exossomo e a RNAs. Neste projeto, a reconstituição in vitro do exossomo da archaea Pyrococcus abyssi formado pela proteína de topo PaCsl4 foi obtida. Para tanto foram realizadas análises de interação proteica usando as técnicas de cromatografia de afinidade, gel filtração e SDS-PAGE. Em adição à formação da isoforma PaCsl4-exossomo, um fragmento peptídico correspondente à região C-terminal da PaNip7 foi sintetizado pelo método da fase sólida, purificado por RP-HPLC e o purificado foi caracterizado por LC/ESI-MS almejando realizar futuros experimentos de interação com o exossomo. / The exosome is a multiprotein complex evolutionarily conserved from archaea to higher eukaryotes that performs essential cellular functions such as: 3\'→5\' exoribonucleolytic activity, regulation of mRNA levels, maturation of structural RNAs and quality control of RNAs during the various stages of the gene expression mechanism. In Archaea, the exosome is composed of up to four different subunits, two with RNase PH domains, aRrp41 and aRrp42, and two with RNAs binding domains, aCsl4 and aRrp4. Three copies of the aRrp4 and/or aCsl4 proteins associate with the hexameric catalytic core of the RNase PH ring and complete the formation of the complex. The PaNip7 protein is a regulating cofactor of the Pyrococcus abyssi archaeal exosome and acts in the inhibition of the enzyme complex by binding simultaneously to the exosome and RNAs. In this project, the reconstitution in vitro of the Pyrococcus abyssi archaeal exosome formed by the PaCsl4 top protein was achieved. To this end protein interaction analyses were performed using affinity chromatography, gel filtration and SDS-PAGE techniques. In addition to the formation of the PaCsl4-exosome isoform, a peptide fragment corresponding to the C-terminal region of PaNip7 was synthesized by solid-phase method, purified by RP-HPLC and the purified peptide was characterized by LC/ESI-MS aiming to perform future binding experiments with the exosome.

Sepsis is the most frequent cause of mortality in most intensive care units. Cardiovascular dysfunction is a major complication associated with sepsis, with high mortality rates up to 70%. Currently, there is no effective treatment approach for sepsis. The integrity of the endothelium is fundamental for the homeostasis of the cardiovascular system. Sepsis induces endothelial cell injury which is the key factor for multiple organ failure. The increased expression of adhesion molecules and chemokines in endothelial cell promotes leukocytes infiltration into the tissue. The loss of tight junction proteins and increased permeability of the endothelial cells will provoke tissue hypoxia and subsequent organ failure. Therefore, preservation of endothelial function is a critical approach for improving sepsis-induced outcome. Here, we showed that endothelial specific protein HSPA12B plays a critical role in the preservation of cardiovascular function in polymicrobial sepsis. HSPA12B is the newest member of HSP70 family which predominantly expresses in endothelial cells. We observed that HSPA12B deficiency (HSPA12B-/-) exaggerated polymicrobial sepsis-induced endothelial dysfunction, leading to worse cardiac dysfunction. HSPA12B-/- significantly increases the expression of adhesion molecules, decreases tight junction protein levels and enhances vascular permeability. HSPA12B-/- alsomarkedly promotes the infiltration of inflammatory cells into the myocardium and inflammatory cytokine production. We investigated the cardioprotective mechanisms of HSPA12B in sepsis induced cardiovascular dysfunction. Exosomes play a critical role in intercellular communication. Exosome is a natural vehicle of microRNAs. We found that exosomes isolated from HSPA12B-/- septic mice induced more expression of adhesion molecules in endothelial cells and inflammation in macrophages. Interestingly, the levels of miR-126 in serum exosomes isolated from HSPA12B-/- septic mice were significantly lowers than in WT septic mice. Importantly, delivery of miR-126 carried exosomes significantly improved cardiac function, suppressed the expression of adhesion molecules, reduced immune cell infiltration in the myocardium, and improved vascular permeability in HSPA12B-/- septic mice. The data suggests that HSPA12B is essential for endothelial function in sepsis and that miR-126 containing exosomes plays a critical role in cardiovascular-protective mechanisms of endothelial HSPA12B in polymicrobial sepsis.

Secretory processes underpin the emergence of cellular diversity in complex multicellular organisms. However, our understanding of the basic mechanisms controlling the different secretory and endosomal compartments involved remains surprisingly incomplete. During my DPhil I have studied a specialised epithelial cell type in the male Drosophila accessory glands, the secondary cell, which contains unusually large intracellular compartments that are accessible to detailed morphological study. I characterise the organisation, ultrastructure and molecular composition of this cell's secretory and endosomal compartments, and I employ specific Rab GTPases, conserved coordinators of membrane trafficking and identity, to define multiple compartmental subtypes. By developing super-resolution and time-lapse microscopy approaches in these cells, I show that numerous intraluminal vesicles (ILVs) are formed within Rab11-labelled secretory compartments and released into the accessory gland lumen as exosomes, the first clear demonstration in eukaryotic cells of exosome biogenesis within a non-late endosomal compartment. Biogenesis of these ILVs is dependent on evolutionarily conserved Endosomal Sorting Complexes Required for Transport (ESCRT) 0-III genes and involves loading of compartment-specific cargoes. Work by others, some in collaboration with me, has shown that these novel mechanisms are conserved in human cells. I show that dense-core granules, the structures employed to package proteins and other molecules destined for regulated secretion, form within large non-cored Rab6- positive compartments, in a process that seems to involve inputs from both the Golgi and recycling endosomal pathways. Further analysis has revealed roles for specific Rabs, for ILVs, and for the conserved fibrillar protein Mfas/TGFBI in different aspects of DCG formation. I also show that DCGs are not only secreted, but can also be degraded by fusion to acidic endosomal compartments. Remarkably, there is evidence that mammalian cells may employ all of these mechanisms and defects in these processes may be linked to diseases like cancer, diabetes and neurodegenerative disorders. Hence my work has established a new system to study complex secretory mechanisms, which can now be developed to model specific disease processes in the future. In summary, I have discovered several novel cell biological mechanisms controlling exosome biology, dense-core granule biogenesis, regulated secretion, and endolysosomal trafficking. Some of these already appear relevant to human health and disease, suggesting that the secondary cell system has considerable further potential for unravelling the fundamental processes underlying eukaryotic secretion in the future.

O exossomo é um complexo multiproteico conservado evolutivamente de archaea a eucariotos superiores que desempenha funções celulares essenciais tais como: atividade exoribonucleolítica 3\'→5\', regulação dos níveis de mRNA, maturação de RNAs estruturais e controle de qualidade de RNAs durante os vários estágios do mecanismo de expressão gênica. Em Archaea, o exossomo é composto por até quatro subunidades diferentes, duas com domínios de RNase PH, aRrp41 e aRrp42, e duas com domínios de ligação a RNAs, aCsl4 e aRrp4. Três cópias das proteínas aRrp4 e/ou aCsl4 se associam com o núcleo hexamérico catalítico do anel de RNase PH e completam a formação do complexo. A proteína PaNip7 é um cofator de regulação do exossomo da archaea Pyrococcus abyssi e atua na inibição do complexo enzimático ligando-se simultaneamente ao exossomo e a RNAs. Neste projeto, a reconstituição in vitro do exossomo da archaea Pyrococcus abyssi formado pela proteína de topo PaCsl4 foi obtida. Para tanto foram realizadas análises de interação proteica usando as técnicas de cromatografia de afinidade, gel filtração e SDS-PAGE. Em adição à formação da isoforma PaCsl4-exossomo, um fragmento peptídico correspondente à região C-terminal da PaNip7 foi sintetizado pelo método da fase sólida, purificado por RP-HPLC e o purificado foi caracterizado por LC/ESI-MS almejando realizar futuros experimentos de interação com o exossomo. / The exosome is a multiprotein complex evolutionarily conserved from archaea to higher eukaryotes that performs essential cellular functions such as: 3\'→5\' exoribonucleolytic activity, regulation of mRNA levels, maturation of structural RNAs and quality control of RNAs during the various stages of the gene expression mechanism. In Archaea, the exosome is composed of up to four different subunits, two with RNase PH domains, aRrp41 and aRrp42, and two with RNAs binding domains, aCsl4 and aRrp4. Three copies of the aRrp4 and/or aCsl4 proteins associate with the hexameric catalytic core of the RNase PH ring and complete the formation of the complex. The PaNip7 protein is a regulating cofactor of the Pyrococcus abyssi archaeal exosome and acts in the inhibition of the enzyme complex by binding simultaneously to the exosome and RNAs. In this project, the reconstitution in vitro of the Pyrococcus abyssi archaeal exosome formed by the PaCsl4 top protein was achieved. To this end protein interaction analyses were performed using affinity chromatography, gel filtration and SDS-PAGE techniques. In addition to the formation of the PaCsl4-exosome isoform, a peptide fragment corresponding to the C-terminal region of PaNip7 was synthesized by solid-phase method, purified by RP-HPLC and the purified peptide was characterized by LC/ESI-MS aiming to perform future binding experiments with the exosome.

Le Myélome Multiple (MM) est une hémopathie maligne caractérisée par la prolifération de plasmocytes tumoraux médullaires. MYC occupe un rôle central dans l'oncogenèse du MM car son activation est responsable de la progression du stade précurseur de MGUS en MM symptomatique. Dans ce travail, nous rapportons que l’expression de LIN28B est corrélée à celle de MYC et est associée à un mauvais pronostic dans le MM. Nous montrons que l'axe LIN28B/let-7 module l'expression de l’ARNm de MYC, lui-même cible de let-7. De plus, la perturbation de l'axe LIN28B/let-7 induit une régulation la prolifération des lignées cellulaires de MM in vitro et in vivo. L'analyse par séquençage d’ARN de modèles de KO par utilisation de la technologie CRISPR a montré que l'axe LIN28B/let-7 régule les voies de signalisation de MYC et du cycle cellulaire dans MM. Nous avons de plus établi une preuve de principe thérapeutique de la possibilité de cibler MYC par l’emploi de LNA-GapmeR contenant une séquence analogue à let-7b. Dans un modèle de xénogreffe murin, nous montrons que des niveaux élevés d'expression de let-7, par administration de LNA-GapmeR let-7b, répriment la croissance tumorale en régulant l’expression de MYC. Ces résultats révèlent un nouveau mécanisme de ciblage thérapeutique de MYC via l'axe LIN28B/let-7 dans MM. Nous nous sommes ensuite intéressés à évaluer de nouvelles formes de biomarqueurs moléculaires dans le MM par étude des miARN contenus dans les exosomes circulants. Nous avons examiné le rôle pronostique des miARN exosomaux dans une cohorte de 156 échantillons de patients uniformément traités pour un MM au diagnostic. Après analyse du profil de miARN exosomaux par séquençage de nouvelle génération, nous avons utilisé technique de qRT-PCR pour étudier la corrélation entre le niveau d’expression de 22 miARN et la survie sans progression (SSP) et la survie globale (SG). Deux miARN, à savoir let-7b et miR-18a, étaient significativement associés à la SSP et SG en analyse univariée, et étaient statistiquement significatifs après ajustement pour le système international de stratification du risque (ISS) et les marqueurs cytogénétique en analyse multivariée. Nos résultats confirment le niveau d’expression des miARN let-7b et miR-18a au sein des exosomes circulants permettent d’améliorer la stratification du risque chez les patients atteints de MM. Enfin, pour mieux comprendre le programme oncogénique piloté par MYC, nous avons étudié l’efficacité thérapeutique d’une librairie de petites sur des lignées cellulaires avec une forte expression de MYC, dans le MM. Les résultats ont permis d’identifier les rocaglates, une famille de composés inhibant l’initiation de la traduction, comme étant les plus actifs. L’étude du profil transcriptionnel par séquençage de l’ARN de lignées cellulaires de MM traitées par CMLD010509 ou DMSO a révélé l’activation d’un programme de transcription et l’inhibition d’un programme traductionnel, caractéristique de l’inactivation de HSF1 secondaire à l’inhibition de la traduction. Le profile traductionnel était étudié par spectrométrie de masse quantitative, permettant d’identifier un ensemble de protéines, tels que MYC, MDM2, CCND1, MAF et MCL-1, spécifiquement affectées par l’inhibition de la traduction liée au composé CMLD010509 dans le MM. Nous avons confirmé l’efficacité thérapeutique des rocaglates dans plusieurs modèles murins de MM. Ces résultats démontrent la possibilité de cibler le programme de traduction oncogénique lié à MYC dans MM. / MYC is a major oncogenic driver of Multiple Myeloma (MM) and yet almost no therapeutic agents exist that target MYC in MM. Here we report that the let-7 biogenesis inhibitor LIN28B correlates with MYC expression in MM and is associated with adverse outcome. We also demonstrate that the LIN28B/let-7 axis modulates the expression of MYC, itself a let-7 target. Further, perturbation of the axis regulates the proliferation of MM cells in vivo in a xenograft tumor model. RNA-sequencing and gene set enrichment analyses of CRISPR-engineered cells suggested that the LIN28/let-7 axis regulates MYC and cell cycle pathways in MM. We provide proof of principle for therapeutic regulation of MYC through let-7 with an LNA-GapmeR (locked nucleic acid-GapmeR) containing a let-7b mimic in vivo, demonstrating that high levels of let-7 expression repress tumor growth by regulating MYC expression. These findings reveal a novel mechanism of therapeutic targeting of MYC through the LIN28B/let-7 axis in MM. We next sought to establish new biomarkers in MM, enable to capture the molecular alterations of the disease. For this purpose, we examined the prognostic significance of circulating exosomal microRNAs (miRNAs) in a cohort of 156 patients with newly diagnosed MM, uniformly treated and followed. Circulating exosomal miRNAs were isolated and used to perform small RNA sequencing analysis on 10 samples and a qRT-PCR array on 156 samples. We studied the relationship between miRNA levels and patient outcomes including progression-free survival (PFS) and overall survival (OS). We identified miRNAs as the most predominant small RNAs present in exosomes isolated from the serum of MM patients and healthy controls by small RNA sequencing of circulating exosomes and used a qRT-PCR assay to measure the expression of 22 exosomal miRNAs. Two of them, namely let-7b and miR-18a, were significantly associated with both PFS and OS in the univariate analysis, and were still statistically significant after adjusting for the International Staging System (ISS), and adverse cytogenetics in the multivariate analysis. Our findings support the use of circulating exosomal let-7b and miR-18a improves the identification of patients with newly diagnosed MM with poor outcomes. Finally, to better understand the oncogenic program driven by MYC and investigate its potential as a therapeutic target, we screened a chemically diverse small molecule library for anti-MM activity in cell lines with high expression of MYC. The most potent hits identified were rocaglate-scaffold inhibitors of translation initiation. Expression profiling of MM cells revealed reversion of the oncogenic MYC-driven transcriptional program by CMLD010509, the most promising rocaglate. Proteome-wide, reversion correlated with selective depletion of short-lived proteins that are key to MM growth and survival, most notably MYC, MDM2, CCND1, MAF, and MCL-1. The efficacy of CMLD010509 in several mouse models of MM confirmed the therapeutic relevance of these findings in vivo and supports the feasibility of targeting the oncogenic MYC-driven translation program in MM with rocaglates.